{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT02129751",
            "orgStudyIdInfo": {
                "id": "V01-BUPA-401"
            },
            "organization": {
                "fullName": "Bausch Health Americas, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder",
            "officialTitle": "A Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder",
            "therapeuticArea": [
                "Other"
            ],
            "study": "efficacy-and-safety-of-bupropion-hydrobromide-in-adolescents-and-children-with-major-depressive-disorder"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-02",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-06",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2014-04-30",
            "studyFirstSubmitQcDate": "2014-05-01",
            "studyFirstPostDateStruct": {
                "date": "2014-05-02",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2023-02-06",
            "lastUpdatePostDateStruct": {
                "date": "2023-02-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Bausch Health Americas, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety",
            "detailedDescription": "* The primary efficacy endpoint is the mean change from Baseline to EOT in total CDRS-R (raw) score.\n* The secondary efficacy endpoints include:\n\n  * Proportion of subjects characterized as responders at EOT (\u226540% improvement from Baseline total CDRS-R raw score)\n  * Proportion of subjects characterized as in remission at EOT (total CDRS-R raw score \\<29)\n  * Mean change from Baseline to EOT in CGI-C.\n\nSafety endpoints include:\n\n* Incidence of AEs\n* Change from Baseline to EOT in vital signs (blood pressure and radial pulse rate), blood and urine laboratory panel, and ECG\n* Treatment discontinuation due to AEs\n* Suicidality as assessed by the C-SSRS score\n* Change from Baseline to EOT in sleep as assessed by the sleep subscale of the CDRS-R."
        },
        "conditionsModule": {
            "conditions": [
                "Major Depressive Disorder"
            ],
            "keywords": [
                "able to swallow medications without difficulty",
                "bupropion hydrobromide"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 200,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "bupropion hydrobromide",
                    "type": "EXPERIMENTAL",
                    "description": "study drug",
                    "interventionNames": [
                        "Drug: bupropion hydrobromide"
                    ]
                },
                {
                    "label": "placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "placebo",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "bupropion hydrobromide",
                    "description": "study drug",
                    "armGroupLabels": [
                        "bupropion hydrobromide"
                    ],
                    "otherNames": [
                        "Aplenzin"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "placebo arm",
                    "armGroupLabels": [
                        "placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Mean change from Baseline to EOT in total CDRS-R (raw) score",
                    "description": "Change from Baseline to EOT in total Children's Depression Rating Scale - Revised (CDRS-R). A higher score indicates a more profound state of depression. The interviewer rates 17 symptom areas; the symptom scores are summed to generate a total score. The total score ranges from 17 to 108.",
                    "timeFrame": "Baseline and 2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female outpatients aged \u22657 to \\<18 years (at Screening Visit 1).\n* Provide assent (subject) and written informed consent (parent/legal representative) and Health Insurance Portability and Accountability Act (HIPAA) for study participation (at Screening Visit 1).\n* Meet diagnostic criteria for MDD as defined in the DSM IV-TR5 at Screening Visits 1 and 1a (K-SADS-PL; see Appendix 17.2).\n* Current depressive episode of at least 4 weeks' duration as noted in the subject's history (Screening Visit 1).\n* Total CDRS-R raw score \u226545 at both the Screening and Baseline Visits (Visits 1 and 2) (see Appendix 17.3).\n* CGI-S score of \u22654 at the Baseline Visit (Visit 2) (see Appendix 17.4).\n\nExclusion Criteria:\n\n* are unable to swallow medications without difficulty\n* have known hypersensitivity to bupropion hydrobromide\n* are pregnant or planning to get pregnant or are lactating\n* Women of childbearing age unable to use at least one method of effective contraception for the duration of the study\n* Previous history of attempted suicide\n* are unable to understand and communicate effectively with parent, Investigator, and study coordinator\n* are at immediate risk of requiring hospitalization, in the Investigator's opinion\n* have current seizure disorder or history of seizures or head trauma\n* have history or presence of clinically significant medical conditions or clinically important laboratory abnormalities\n* have ECG or physical examination abnormality at screening\n* have body weight less than the 3rd percentile or greater than the 97th percentile for age.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "7 Years",
            "maximumAge": "17 Years",
            "stdAges": [
                "CHILD"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Tendai Merriweather",
                    "role": "CONTACT",
                    "phone": "908-541-2720",
                    "email": "tendai.merriweather@bauschhealth.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Johnson Varughese",
                    "affiliation": "Bausch Health Americas, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Valeant",
                    "city": "Bridgewater",
                    "state": "New Jersey",
                    "zip": "08807",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "not available not available, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.60079,
                        "lon": -74.64815
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003866",
                    "term": "Depressive Disorder"
                },
                {
                    "id": "D000003863",
                    "term": "Depression"
                },
                {
                    "id": "D000003865",
                    "term": "Depressive Disorder, Major"
                }
            ],
            "ancestors": [
                {
                    "id": "D000019964",
                    "term": "Mood Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                },
                {
                    "id": "D000001526",
                    "term": "Behavioral Symptoms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7058",
                    "name": "Depression",
                    "asFound": "Depressive Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7061",
                    "name": "Depressive Disorder",
                    "asFound": "Depressive Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7060",
                    "name": "Depressive Disorder, Major",
                    "asFound": "Major Depressive Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21835",
                    "name": "Mood Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4818",
                    "name": "Behavioral Symptoms",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000016642",
                    "term": "Bupropion"
                }
            ],
            "ancestors": [
                {
                    "id": "D000018687",
                    "term": "Antidepressive Agents, Second-Generation"
                },
                {
                    "id": "D000000928",
                    "term": "Antidepressive Agents"
                },
                {
                    "id": "D000011619",
                    "term": "Psychotropic Drugs"
                },
                {
                    "id": "D000018765",
                    "term": "Dopamine Uptake Inhibitors"
                },
                {
                    "id": "D000014179",
                    "term": "Neurotransmitter Uptake Inhibitors"
                },
                {
                    "id": "D000049990",
                    "term": "Membrane Transport Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000015259",
                    "term": "Dopamine Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000065690",
                    "term": "Cytochrome P-450 CYP2D6 Inhibitors"
                },
                {
                    "id": "D000065607",
                    "term": "Cytochrome P-450 Enzyme Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M19013",
                    "name": "Bupropion",
                    "asFound": "Apnea",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4247",
                    "name": "Antidepressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M14474",
                    "name": "Psychotropic Drugs",
                    "relevance": "LOW"
                },
                {
                    "id": "M7473",
                    "name": "Dopamine",
                    "relevance": "LOW"
                },
                {
                    "id": "M20832",
                    "name": "Dopamine Uptake Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M17962",
                    "name": "Dopamine Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M30537",
                    "name": "Cytochrome P-450 Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "CaAg",
                    "name": "Cardiotonic Agents"
                }
            ]
        }
    },
    "hasResults": false
}